Current Hypertension Management Guidelines

Blood Pressure Diagnostic Thresholds

The ACC/AHA 2017 guideline defines hypertension as ≥130/80 mmHg, while the 2024 European Society of Cardiology and WHO retain the traditional ≥140/90 mmHg threshold. 1 This creates an international divergence, with the lower ACC/AHA threshold increasing U.S. prevalence from 32% to 46% of adults. 1

ACC/AHA Classification:

Normal: <120/80 mmHg 1
Elevated: 120–129/<80 mmHg 1
Stage 1: 130–139/80–89 mmHg 1
Stage 2: ≥140/90 mmHg 1

Diagnostic Confirmation:

Diagnosis requires the average of ≥2 readings on ≥2 separate occasions 1
Confirm with out-of-office monitoring before starting medication (home BP ≥135/85 mmHg or 24-hour ambulatory ≥130/80 mmHg) to exclude white-coat hypertension 1, 2

Blood Pressure Treatment Targets

For most adults, target <130/80 mmHg based on ACC/AHA guidelines, which show a ≈25% reduction in cardiovascular events and ≈27% reduction in all-cause mortality at this goal. 1

Specific Population Targets:

General adults <65 years: <130/80 mmHg (Class I, Level A) 1
Adults ≥65 years (ambulatory, non-institutionalized): systolic <130 mmHg if tolerated 1
Diabetes mellitus: <130/80 mmHg 1
Chronic kidney disease: <130/80 mmHg 1
Stable ischemic heart disease: <130/80 mmHg 1
Post-stroke/TIA: <130/80 mmHg may be reasonable 1

Critical Diastolic Consideration:

In high-risk patients, do not lower diastolic below 60–70 mmHg; optimal diastolic range is 70–79 mmHg to avoid compromising coronary perfusion. 1

Lifestyle Modifications

All individuals with BP ≥120/70 mmHg should adopt lifestyle measures immediately, not sequentially after failed pharmacotherapy. 1 This includes:

Weight management (target BMI <25 kg/m²) 1
DASH diet (rich in fruits, vegetables, low-fat dairy) 1
Sodium restriction (<2.3 g/day, ideally <1.5 g/day) 1
Regular aerobic activity (≥150 min/week moderate intensity) 1
Alcohol moderation (≤2 drinks/day men, ≤1 drink/day women) 1
Smoking cessation 1

When to Initiate Pharmacologic Therapy

Stage 1 Hypertension (130–139/80–89 mmHg):

Start medication when:

10-year ASCVD risk ≥10% (calculated via ACC/AHA Pooled Cohort Equations) 1, 2
Established cardiovascular disease 1
Diabetes mellitus 1
Chronic kidney disease 1
Hypertension-mediated organ damage 1

If none of the above apply, continue lifestyle measures for 3 months; add medication if BP remains ≥130/80 mmHg. 1

Stage 2 Hypertension (≥140/90 mmHg):

Initiate lifestyle measures AND pharmacologic therapy simultaneously; do not delay beyond 3 months. 1, 2 Virtually all adults ≥70 years and most ≥65 years have 10-year ASCVD risk ≥10% and therefore meet treatment threshold even at Stage 1 levels. 1

First-Line Pharmacologic Agents

Four drug classes are endorsed as first-line therapy: thiazide/thiazide-like diuretics, ACE inhibitors, ARBs, and long-acting dihydropyridine calcium-channel blockers (CCBs). 1 All produce comparable office BP reductions of ≈9/5 mmHg and ambulatory reductions of ≈5/3 mmHg as monotherapy. 1

Optimal First-Line Choice for General Population:

Thiazide-like diuretics (especially chlorthalidone 12.5–25 mg daily) are the optimal first-line agent because the ALLHAT trial (>50,000 participants) demonstrated superior prevention of heart failure (38% reduction vs. amlodipine) and stroke (15% reduction vs. lisinopril). 1 Chlorthalidone's 40–60 hour half-life provides 24-hour BP control. 1

Monotherapy vs. Combination Strategy

Stage 1 Hypertension:

Start with single-agent monotherapy (chlorthalidone 12.5 mg or amlodipine 5 mg) and titrate upward before adding a second class. 1 Reassess monthly until target is achieved. 1

Stage 2 Hypertension:

Begin with a two-drug combination from different first-line classes, preferably as a single-pill formulation. 1, 2 Single-pill combinations markedly improve adherence and persistence. 1 Two submaximal doses from different classes yield larger BP reductions with fewer adverse effects than maximal dosing of a single agent. 1

Preferred Two-Drug Combinations:

ACE inhibitor or ARB + thiazide-like diuretic (optimal for general population) 1
ACE inhibitor or ARB + long-acting dihydropyridine CCB (when thiazides contraindicated) 1

Population-Specific Recommendations

Black Patients (Without Heart Failure or CKD):

Initiate with thiazide diuretic or CCB rather than ACE inhibitor/ARB, because renin-angiotensin system blockers are ≈30–36% less effective for stroke prevention in this group due to lower renin activity. 1 ARBs may cause less cough and angioedema than ACE inhibitors but provide no additional cardiovascular benefit. 1

Diabetes Mellitus:

Prefer ACE inhibitor or ARB as initial therapy to preserve renal function, especially when albuminuria ≥300 mg/day is present. 1 Target <130/80 mmHg. 1

Chronic Kidney Disease (Stage 3+ or Albuminuria):

ACE inhibitor or ARB is first-line to decelerate eGFR decline and reduce proteinuria. 1 Target <130/80 mmHg. 1 An increase in creatinine up to 50% above baseline or to 3 mg/dL (whichever is greater) is acceptable. 1

Post-Myocardial Infarction or Stable Ischemic Heart Disease:

Combine β-blocker with ACE inhibitor or ARB as foundational therapy. 1 If angina persists and BP remains uncontrolled, add a dihydropyridine CCB. 1 Continue β-blocker for ≥3 years post-MI. 1 Target <130/80 mmHg. 1

Heart Failure with Reduced Ejection Fraction:

Use three-drug regimen: ACE inhibitor or ARB + β-blocker + diuretic. 1

Pregnancy:

Switch to methyldopa, extended-release nifedipine, or labetalol. 1 ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated due to fetal toxicity. 1

Older Adults (≥85 years):

Continue BP-lowering therapy lifelong if well tolerated; asymptomatic orthostatic hypotension alone should not prompt withdrawal. 1 For frail patients or those with limited life expectancy, individualized clinical judgment is reasonable, but treatment may be deferred until BP exceeds 140/90 mmHg. 1

Escalation to Triple Therapy

If BP remains ≥140/90 mmHg despite dual therapy at optimal doses, add a third agent to create the standard triple regimen: ACE inhibitor or ARB + CCB + thiazide-like diuretic, preferably as a single-pill combination. 1, 2 Prior to adding the third agent, optimize the doses of the first two drugs. 2

Resistant Hypertension (≥130/80 mmHg on ≥3 agents including a diuretic):

Confirm true resistance with out-of-office monitoring and assess adherence 1
Identify contributing factors (obesity, excess alcohol, high sodium, NSAIDs, obstructive sleep apnea) 1
Screen for secondary causes (primary aldosteronism, renal artery stenosis, pheochromocytoma) 1
Optimize diuretic therapy; use loop diuretics in CKD 1
Add mineralocorticoid-receptor antagonist (spironolactone) 1
Refer to hypertension specialist if uncontrolled after 6 months 1

Monitoring and Follow-Up

After initiating or adjusting therapy, review patients monthly until BP target is achieved, then every 3–5 months for maintenance. 1 Dose adjustments should be spaced ≥4 weeks apart to allow full BP response. 1

Baseline Laboratory Evaluation:

Serum creatinine, eGFR, potassium 1
Fasting glucose or HbA1c 1
Lipid panel 1
Urine albumin 1

When Prescribing ACE Inhibitors, ARBs, or Diuretics:

Repeat creatinine, eGFR, and potassium within 1–2 weeks of initiation, after each dose increase, and annually thereafter. 1, 3

Out-of-Office Monitoring:

Home or ambulatory BP monitoring is essential to assess treatment response, detect white-coat effect, and identify masked uncontrolled hypertension. 1

Critical Agents to Avoid as First-Line

β-Blockers:

Should not be used as first-line in uncomplicated hypertension, especially in patients >60 years, because they are ≈36% less effective than CCBs and ≈30% less effective than thiazides for stroke prevention. 1 Reserve for compelling indications (angina, post-MI, HFrEF, atrial fibrillation). 1

α-Blockers:

Not first-line because they are less effective for cardiovascular disease prevention than thiazide diuretics. 1 In ALLHAT, doxazosin was associated with an 80% higher rate of heart failure compared with chlorthalidone. 1

Hydrochlorothiazide <25 mg Daily:

Discouraged as monotherapy because such low doses are unproven or less effective in outcome trials. 1

Contraindicated Combinations

Never combine an ACE inhibitor with an ARB (or add aliskiren) because dual renin-angiotensin system blockade increases risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. 1, 2, 3

Common Pitfalls to Avoid

Delaying combination therapy in Stage 2 hypertension increases cardiovascular risk 1
Using β-blockers as first-line in patients >60 years without compelling indication leads to inferior stroke prevention 1
Excessive diastolic lowering below 60 mmHg in high-risk patients may increase adverse cardiovascular events 1
Failing to employ out-of-office BP monitoring can miss white-coat or masked hypertension 1
Assuming treatment failure before confirming medication adherence, as non-adherence is the most common cause of apparent resistance 2
Continuing ACE inhibitors or ARBs during pregnancy is contraindicated due to fetal toxicity 1

What are the current guideline recommendations for managing primary hypertension in adults, including blood pressure targets, lifestyle modifications, first‑line pharmacologic classes, and adjustments for age, race, diabetes, or chronic kidney disease?

Help us tailor your experience